Neurotransmitter

A neurotransmitter is a signaling molecule secreted by a neuron to affect another cell across a synapse. The cell receiving the signal, or target cell, may be another neuron, but could also be a gland or muscle cell.

Postsynaptic
density

Voltage-
gated Ca⁺⁺
channel

Synaptic
vesicle

Neurotransmitter
transporter

Receptor

Neurotransmitter

Axon terminal

Synaptic cleft

Dendrite

Structure of a typical chemical synapse

Neurotransmitters are released from synaptic vesicles into the synaptic cleft where they are able to interact with neurotransmitter receptors on the target cell. Some neurotransmitters are also stored in large dense core vesicles. The neurotransmitter's effect on the target cell is determined by the receptor it binds to. Many neurotransmitters are synthesized from simple and plentiful precursors such as amino acids, which are readily available and often require a small number of biosynthetic steps for conversion.

Neurotransmitters are essential to the function of complex neural systems. The exact number of unique neurotransmitters in humans is unknown, but more than 100 have been identified. Common neurotransmitters include glutamate, GABA, acetylcholine, glycine, dopamine and norepinephrine.

Mechanism and cycle

Synthesis

Neurotransmitters are generally synthesized in neurons and are made up of, or derived from, precursor molecules that are found abundantly in the cell. Classes of neurotransmitters include amino acids, monoamines, and peptides. Monoamines are synthesized by altering a single amino acid. For example, the precursor of serotonin is the amino acid tryptophan. Peptide neurotransmitters, or neuropeptides, are protein transmitters which are larger than the classical small-molecule neurotransmitters and are often released together to elicit a modulatory effect. Purine neurotransmitters, like ATP, are derived from nucleic acids. Metabolic products such as nitric oxide and carbon monoxide have also been reported to act like neurotransmitters.

	Examples
Amino acids	glycine, glutamate
Monoamines	serotonin, epinephrine, dopamine
Peptides	substance P, opioids
Purines	ATP, GTP
Other	nitric oxide, carbon monoxide

Storage

Synaptic vesicles containing neurotransmitters

Neurotransmitters are generally stored in synaptic vesicles, clustered close to the cell membrane at the axon terminal of the presynaptic neuron. However, some neurotransmitters, like the metabolic gases carbon monoxide and nitric oxide, are synthesized and released immediately following an action potential without ever being stored in vesicles.

Release

Generally, a neurotransmitter is released via exocytosis at the presynaptic terminal in response to an electrical signal called an action potential in the presynaptic neuron. However, low-level "baseline" release also occurs without electrical stimulation. Neurotransmitters are released into and diffuse across the synaptic cleft, where they bind to specific receptors on the membrane of the postsynaptic neuron.

Receptor interaction

After being released into the synaptic cleft, neurotransmitters diffuse across the synapse where they are able to interact with receptors on the target cell. The effect of the neurotransmitter is dependent on the identity of the target cell's receptors present at the synapse. Depending on the receptor, binding of neurotransmitters may cause excitation, inhibition, or modulation of the postsynaptic neuron.

Elimination

Acetylcholine is cleaved in the synaptic cleft into acetic acid and choline.

In order to avoid continuous activation of receptors on the post-synaptic or target cell, neurotransmitters must be removed from the synaptic cleft. Neurotransmitters are removed through one of three mechanisms:

1. Diffusion – neurotransmitters drift out of the synaptic cleft, where they are absorbed by glial cells. These glial cells, usually astrocytes, absorb the excess neurotransmitters.
   • Astrocytes, a type of glial cell in the brain, actively contribute to synaptic communication through astrocytic diffusion or gliotransmission. Neuronal activity triggers an increase in astrocytic calcium levels, prompting the release of gliotransmitters, such as glutamate, ATP, and D-serine. These gliotransmitters diffuse into the extracellular space, interacting with nearby neurons and influencing synaptic transmission. By regulating extracellular neurotransmitter levels, astrocytes help maintain proper synaptic function. This bidirectional communication between astrocytes and neurons add complexity to brain signaling, with implications for brain function and neurological disorders.
2. Enzyme degradation – proteins called enzymes break the neurotransmitters down.
3. Reuptake – neurotransmitters are reabsorbed into the pre-synaptic neuron. Transporters, or membrane transport proteins, pump neurotransmitters from the synaptic cleft back into axon terminals (the presynaptic neuron) where they are stored for reuse.

For example, acetylcholine is eliminated by having its acetyl group cleaved by the enzyme acetylcholinesterase; the remaining choline is then taken in and recycled by the pre-synaptic neuron to synthesize more acetylcholine. Other neurotransmitters are able to diffuse away from their targeted synaptic junctions and are eliminated from the body via the kidneys, or destroyed in the liver. Each neurotransmitter has very specific degradation pathways at regulatory points, which may be targeted by the body's regulatory system or medication. Cocaine blocks a dopamine transporter responsible for the reuptake of dopamine. Without the transporter, dopamine diffuses much more slowly from the synaptic cleft and continues to activate the dopamine receptors on the target cell.

Discovery

Until the early 20th century, scientists assumed that the majority of synaptic communication in the brain was electrical. However, through histological examinations by Ramón y Cajal, a 20 to 40 nm gap between neurons, known today as the synaptic cleft, was discovered. The presence of such a gap suggested communication via chemical messengers traversing the synaptic cleft, and in 1921 German pharmacologist Otto Loewi confirmed that neurons can communicate by releasing chemicals. Through a series of experiments involving the vagus nerves of frogs, Loewi was able to manually slow the heart rate of frogs by controlling the amount of saline solution present around the vagus nerve. Upon completion of this experiment, Loewi asserted that sympathetic regulation of cardiac function can be mediated through changes in chemical concentrations. Furthermore, Otto Loewi is credited with discovering acetylcholine (ACh) – the first known neurotransmitter.

Identification

To identify neurotransmitters, the following criteria are typically considered:

1. Synthesis: The chemical must be produced within the neuron or be present in it as a precursor molecule.
2. Release and response: When the neuron is activated, the chemical must be released and elicit a response in target cells or neurons.
3. Experimental response: Application of the chemical directly to the target cells should produce the same response observed when the chemical is naturally released from neurons.
4. Removal mechanism: There must be a mechanism in place to remove the neurotransmitter from its site of action once its signaling role is complete.

However, given advances in pharmacology, genetics, and chemical neuroanatomy, the term "neurotransmitter" can be applied to chemicals that:

• Carry messages between neurons via influence on the postsynaptic membrane.
• Have little or no effect on membrane voltage, but have a common carrying function such as changing the structure of the synapse.
• Communicate by sending reverse-direction messages that affect the release or reuptake of transmitters.

The anatomical localization of neurotransmitters is typically determined using immunocytochemical techniques, which identify the location of either the transmitter substances themselves or of the enzymes that are involved in their synthesis. Immunocytochemical techniques have also revealed that many transmitters, particularly the neuropeptides, are co-localized, that is, a neuron may release more than one transmitter from its synaptic terminal. Various techniques and experiments such as staining, stimulating, and collecting can be used to identify neurotransmitters throughout the central nervous system.

Actions

Neurons communicate with each other through synapses, specialized contact points where neurotransmitters transmit signals. When an action potential reaches the presynaptic terminal, the action potential can trigger the release of neurotransmitters into the synaptic cleft. These neurotransmitters then bind to receptors on the postsynaptic membrane, influencing the receiving neuron in either an inhibitory or excitatory manner. If the overall excitatory influences outweigh the inhibitory influences, the receiving neuron may generate its own action potential, continuing the transmission of information to the next neuron in the network. This process allows for the flow of information and the formation of complex neural networks.

Modulation

A neurotransmitter may have an excitatory, inhibitory or modulatory effect on the target cell. The effect is determined by the receptors the neurotransmitter interacts with at the post-synaptic membrane. Neurotransmitter influences trans-membrane ion flow either to increase (excitatory) or to decrease (inhibitory) the probability that the cell with which it comes in contact will produce an action potential. Synapses containing receptors with excitatory effects are called Type I synapses, while Type II synapses contain receptors with inhibitory effects. Thus, despite the wide variety of synapses, they all convey messages of only these two types. The two types are different appearance and are primarily located on different parts of the neurons under its influence. Receptors with modulatory effects are spread throughout all synaptic membranes and binding of neurotransmitters sets in motion signaling cascades that help the cell regulate its function. Binding of neurotransmitters to receptors with modulatory effects can have many results. For example, it may result in an increase or decrease in sensitivity to future stimulus by recruiting more or less receptors to the synaptic membrane.^{[citation needed]}

Type I (excitatory) synapses are typically located on the shafts or the spines of dendrites, whereas type II (inhibitory) synapses are typically located on a cell body. In addition, Type I synapses have round synaptic vesicles, whereas the vesicles of type II synapses are flattened. The material on the presynaptic and post-synaptic membranes is denser in a Type I synapse than it is in a Type II, and the Type I synaptic cleft is wider. Finally, the active zone on a Type I synapse is larger than that on a Type II synapse.^{[citation needed]}

The different locations of Type I and Type II synapses divide a neuron into two zones: an excitatory dendritic tree and an inhibitory cell body. From an inhibitory perspective, excitation comes in over the dendrites and spreads to the axon hillock to trigger an action potential. If the message is to be stopped, it is best stopped by applying inhibition on the cell body, close to the axon hillock where the action potential originates. Another way to conceptualize excitatory–inhibitory interaction is to picture excitation overcoming inhibition. If the cell body is normally in an inhibited state, the only way to generate an action potential at the axon hillock is to reduce the cell body's inhibition. In this "open the gates" strategy, the excitatory message is like a racehorse ready to run down the track, but first, the inhibitory starting gate must be removed.

Neurotransmitter actions

As explained above, the only direct action of a neurotransmitter is to activate a receptor. Therefore, the effects of a neurotransmitter system depend on the connections of the neurons that use the transmitter, and the chemical properties of the receptors.

• Glutamate is used at the great majority of fast excitatory synapses in the brain and spinal cord. It is also used at most synapses that are "modifiable", i.e. capable of increasing or decreasing in strength. Modifiable synapses are thought to be the main memory-storage elements in the brain. Excessive glutamate release can overstimulate the brain and lead to excitotoxicity causing cell death resulting in seizures or strokes. Excitotoxicity has been implicated in certain chronic diseases including ischemic stroke, epilepsy, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington disease, and Parkinson's disease.
• GABA is used at the great majority of fast inhibitory synapses in virtually every part of the brain. Many sedative/tranquilizing drugs act by enhancing the effects of GABA.
• Glycine is the primary inhibitory neurotransmitter in the spinal cord.
• Acetylcholine was the first neurotransmitter discovered in the peripheral and central nervous systems. It activates skeletal muscles in the somatic nervous system and may either excite or inhibit internal organs in the autonomic system. It is main neurotransmitter at the neuromuscular junction connecting motor nerves to muscles. The paralytic arrow-poison curare acts by blocking transmission at these synapses. Acetylcholine also operates in many regions of the brain as a neuromodulatory, but using different types of receptors, including nicotinic and muscarinic receptors.
• Dopamine has a number of important functions in the brain. This includes critical role in the reward system, motivation and emotional arousal. It also plays an important role in fine motor control and Parkinson's disease has been linked to low levels of dopamine due to the loss of dopaminergic neurons in substantia nigra pars compacta.Schizophrenia, a highly heterogeneous and complicated disorder has been linked to high levels of dopamine.
• Serotonin is a monoamine neurotransmitter. Most of it is produced by the intestine (approximately 90%), and the remainder by central nervous system neurons at the raphe nuclei. It functions to regulate appetite, sleep, memory and learning, temperature, mood, behaviour, muscle contraction, and the functions of the cardiovascular system and endocrine system. It is speculated to have a role in depression, as some depressed patients have been reported to exhibit lower concentrations of metabolites of serotonin in their cerebrospinal fluid and brain tissue.
• Norepinephrine is a member of the catecholamine family of neurotransmitters. It is synthesized from the amino acid tyrosine. In the peripheral nervous system, one of the primary roles of norepinephrine is to stimulate the release of the stress hormone epinephrine (i.e. adrenaline) from the adrenal glands. Norepinephrine is involved in the fight-or-flight response and is also affected in anxiety disorders and depression.
• Epinephrine, a neurotransmitter and hormone is synthesized from tyrosine. It is released from the adrenal glands and also plays a role in the fight-or-flight response. Epinephrine has vasoconstrictive effects, which promote increased heart rate, blood pressure, energy mobilization. Vasoconstriction influences metabolism by promoting the breakdown of glucose released into the bloodstream. Epinephrine also has bronchodilation effects, which is the relaxing of airways.

Types

There are many different ways to classify neurotransmitters and are commonly classified into amino acids, monoamines and peptides.

Some of the major neurotransmitters are:

• Amino acids: glutamate,aspartate, D-serine, gamma-Aminobutyric acid (GABA),glycine
• Gasotransmitters: nitric oxide (NO), carbon monoxide (CO), hydrogen sulfide (H₂S)
• Monoamines:
  • Catecholamines: dopamine (DA), norepinephrine (noradrenaline, NE), epinephrine (adrenaline)
  • Indolamines: serotonin (5-HT, SER), melatonin
  • histamine
• Trace amines: phenethylamine, N-methylphenethylamine, tyramine, 3-iodothyronamine, octopamine, tryptamine, etc.
• Peptides: oxytocin, somatostatin, substance P, cocaine and amphetamine regulated transcript, opioid peptides
• Purines: adenosine triphosphate (ATP), adenosine
• Others: acetylcholine (ACh), anandamide, etc.

In addition, over 100 neuroactive peptides have been found, and new ones are discovered regularly. Many of these are co-released along with a small-molecule transmitter. Nevertheless, in some cases, a peptide is the primary transmitter at a synapse. Beta-Endorphin is a relatively well-known example of a peptide neurotransmitter because it engages in highly specific interactions with opioid receptors in the central nervous system.^{[citation needed]}

Single ions (such as synaptically released zinc) are also considered neurotransmitters by some, as well as some gaseous molecules such as nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H₂S). The gases are produced in the neural cytoplasm and are immediately diffused through the cell membrane into the extracellular fluid and into nearby cells to stimulate production of second messengers. Soluble gas neurotransmitters are difficult to study, as they act rapidly and are immediately broken down, existing for only a few seconds.^{[citation needed]}

The most prevalent transmitter is glutamate, which is excitatory at well over 90% of the synapses in the human brain. The next most prevalent is gamma-Aminobutyric Acid, or GABA, which is inhibitory at more than 90% of the synapses that do not use glutamate. Although other transmitters are used in fewer synapses, they may be very important functionally: the great majority of psychoactive drugs exert their effects by altering the actions of some neurotransmitter systems, often acting through transmitters other than glutamate or GABA. Addictive drugs such as cocaine and amphetamines exert their effects primarily on the dopamine system. The addictive opiate drugs exert their effects primarily as functional analogs of opioid peptides, which, in turn, regulate dopamine levels.^{[citation needed]}

List of neurotransmitters, peptides, and gaseous signaling molecules

Neurotransmitters Category Name Abbreviation Metabotropic Ionotropic SmallTooltip Small molecule: Amino acids (Arg) Arginine Arg, R α2-Adrenergic receptors, imidazoline receptors NMDA receptors Small: Amino acids Aspartate Asp, D – NMDA receptors Small: Amino acids Glutamate Glu, E Metabotropic glutamate receptors NMDA receptors, kainate receptors, AMPARs Small: Amino acids Gamma-aminobutyric acid GABA GABAB receptors GABAA receptors, GABAA-ρ receptors Small: Amino acids Glycine Gly, G – NMDA receptors, glycine receptors Small: Amino acids D-serine Ser, S – NMDA receptors Small: Acetylcholine Acetylcholine ACh Muscarinic acetylcholine receptors Nicotinic acetylcholine receptors Small: Monoamine (Phe/Tyr) Dopamine DA Dopamine receptors, trace amine-associated receptor 1 – Small: Monoamine (Phe/Tyr) Norepinephrine (noradrenaline) NE, NAd Adrenergic receptors – Small: Monoamine (Phe/Tyr) Epinephrine (adrenaline) Epi, Ad Adrenergic receptors – Small: Monoamine (Trp) Serotonin (5-hydroxytryptamine) 5-HT Serotonin receptors (all except 5-HT3) 5-HT3 Small: Monoamine (His) Histamine H Histamine receptors – Small: Trace amine (Phe) Phenethylamine PEA Trace amine-associated receptors TAAR1, TAAR2 – Small: Trace amine (Phe) N-methylphenethylamine NMPEA TAAR1 – Small: Trace amine (Phe/Tyr) Tyramine TYR TAAR1, TAAR2 – Small: Trace amine (Phe/Tyr) octopamine Oct TAAR1 – Small: Trace amine (Phe/Tyr) Synephrine Syn TAAR1 – Small: Trace amine (Trp) Tryptamine TAAR1, various serotonin receptors – Small: Trace amine (Trp) N-methyltryptamine NMT TAAR1, various serotonin receptors – Lipid Anandamide AEA Cannabinoid receptors – Lipid 2-Arachidonoylglycerol 2-AG Cannabinoid receptors – Lipid 2-Arachidonyl glyceryl ether 2-AGE Cannabinoid receptors – Lipid N-Arachidonoyl dopamine NADA Cannabinoid receptors TRPV1 Lipid Virodhamine Cannabinoid receptors – Small: Purine Adenosine Ado Adenosine receptors – Small: Purine Adenosine triphosphate ATP P2Y receptors P2X receptors Small: Purine Nicotinamide adenine dinucleotide β-NAD P2Y receptors P2X receptors Neuropeptides Category Name Abbreviation Metabotropic Ionotropic Bombesin-like peptides Bombesin BBR1-2-3 – Bombesin-like peptide Gastrin releasing peptide GRP – – Bombesin-like peptide Neuromedin B NMB Neuromedin B receptor – Bradykinins Bradykinin B1, B2 – Calcitonin/CGRP family Calcitonin Calcitonin receptor – Calcitonin/CGRP family Calcitonin gene-related peptide CGRP CALCRL – Corticotropin-releasing factors Corticotropin-releasing hormone CRH CRHR1 – Corticotropin-releasing factors Urocortin CRHR1 – Galanins Galanin GALR1, GALR2, GALR3 – Galanins Galanin-like peptide GALR1, GALR2, GALR3 – Gastrins Gastrin Cholecystokinin B receptor – Gastrins Cholecystokinin CCK Cholecystokinin receptors – Granins Chromogranin A ChgA – – Melanocortins Adrenocorticotropic hormone ACTH ACTH receptor – Melanocortins Proopiomelanocortin POMC Melanocortin 4 receptor – Melanocortins Melanocyte-stimulating hormones MSH Melanocortin receptors – Neurohypophyseals Vasopressin AVP Vasopressin receptors – Neurohypophyseals Oxytocin OT Oxytocin receptor – Neurohypophyseals Neurophysin I – – Neurohypophyseals Neurophysin II – – Neurohypophyseals Copeptin – – Neuromedins Neuromedin U NmU NmUR1, NmUR2 – Neuropeptide B/W Neuropeptide B NPB NPBW1, NPBW2 – Neuropeptide B/W Neuropeptide S NPS Neuropeptide S receptors – Neuropeptide Y Neuropeptide Y NY Neuropeptide Y receptors – Neuropeptide Y Pancreatic polypeptide PP – – Neuropeptide Y Peptide YY PYY – – Opioids Enkephalins δ-Opioid receptor – Opioids Dynorphins κ-Opioid receptor – Opioids Neoendorphins κ-Opioid receptor – Opioids Endorphins μ-Opioid receptors – Opioids Endomorphins μ-Opioid receptors – Opioids Morphine μ-Opioid receptors – Opioids Nociceptin/orphanin FQ N/OFQ Nociceptin receptors – Orexins Orexin A OX-A Orexin receptors – Orexins Orexin B OX-B Orexin receptors – Parathyroid hormone family Parathyroid hormone-related protein PTHrP – – RFamides Kisspeptin KiSS GPR54 – RFamides Neuropeptide FF NPFF NPFF1, NPFF2 – RFamides Prolactin-releasing peptide PrRP PrRPR – RFamides Pyroglutamylated RFamide peptide QRFP GPR103 – Secretins Secretin Secretin receptor – Secretins Motilin Motilin receptor – Secretins Glucagon Glucagon receptor – Secretins Glucagon-like peptide-1 GLP-1 Glucagon-like peptide 1 receptor – Secretins Glucagon-like peptide-2 GLP-2 Glucagon-like peptide 2 receptor – Secretins Vasoactive intestinal peptide VIP Vasoactive intestinal peptide receptors – Secretins Growth hormone–releasing hormone GHRH Growth hormone–releasing hormone receptor – Secretins Pituitary adenylate cyclase-activating peptide PACAP ADCYAP1R1 – Somatostatins Somatostatin Somatostatin receptors – Tachykinins Neurokinin A – – Tachykinins Neurokinin B – – Tachykinins Substance P – – Tachykinins Neuropeptide K – – Other Agouti-related peptide AgRP Melanocortin receptor – Other N-Acetylaspartylglutamate NAAG Metabotropic glutamate receptor 3 (mGluR3) – Other Cocaine- and amphetamine-regulated transcript CART Unknown Gi/Go-coupled receptor – Other Gonadotropin-releasing hormone GnRH GnRHR – Other Thyrotropin-releasing hormone TRH TRHR – Other Melanin-concentrating hormone MCH MCHR 1,2 – Gasotransmitters Category Name Abbreviation Metabotropic Ionotropic Gaseous signaling molecule Nitric oxide NO Soluble guanylyl cyclase – Gaseous signaling molecule Carbon monoxide CO – Heme bound to potassium channels Gaseous signaling molecule Hydrogen sulfide H2S – –

Neurotransmitter systems

Neurons expressing certain types of neurotransmitters sometimes form distinct systems, where activation of the system affects large volumes of the brain, called volume transmission. Major neurotransmitter systems include the noradrenaline (norepinephrine) system, the dopamine system, the serotonin system, and the cholinergic system, among others. Trace amines have a modulatory effect on neurotransmission in monoamine pathways (i.e., dopamine, norepinephrine, and serotonin pathways) throughout the brain via signaling through trace amine-associated receptor 1. A brief comparison of these systems follows:

Neurotransmitter systems in the brain

System	Pathway origin and projections	Regulated cognitive processes and behaviors
Noradrenaline system	Noradrenergic pathways: Locus coeruleus (LC) projections LC → Amygdala and Hippocampus LC → Brain stem and Spinal cord LC → Cerebellum LC → Cerebral cortex LC → Hypothalamus LC → Tectum LC → Thalamus LC → Ventral tegmental area Lateral tegmental field (LTF) projections LTF → Brain stem and Spinal cord LTF → Olfactory bulb	anxiety arousal (wakefulness) circadian rhythm cognitive control and working memory (co-regulated by dopamine) feeding and energy homeostasis medullary control of respiration negative emotional memory nociception (perception of pain) reward (minor role)
Dopamine system	Dopaminergic pathways: Ventral tegmental area (VTA) projections VTA → Amygdala VTA → Cingulate cortex VTA → Hippocampus VTA → Ventral striatum (Mesolimbic pathway) VTA → Olfactory bulb VTA → Prefrontal cortex (Mesocortical pathway) Nigrostriatal pathway Substantia nigra pars compacta → Dorsal striatum Tuberoinfundibular pathway Arcuate nucleus → Median eminence Hypothalamospinal projection Hypothalamus → Spinal cord Incertohypothalamic pathway Zona incerta → Hypothalamus	arousal (wakefulness) aversion cognitive control and working memory (co-regulated by norepinephrine) emotion and mood motivation (motivational salience) motor function and control positive reinforcement reward (primary mediator) sexual arousal, orgasm, and refractory period (via neuroendocrine regulation)
Histamine system	Histaminergic pathways: Tuberomammillary nucleus (TMN) projections TMN → Cerebral cortex TMN → Hippocampus TMN → Neostriatum TMN → Nucleus accumbens TMN → Amygdala TMN → Hypothalamus	arousal (wakefulness) feeding and energy homeostasis learning memory
Serotonin system	Serotonergic pathways: Caudal nuclei (CN): Raphe magnus, raphe pallidus, and raphe obscurus Caudal projections CN → Cerebral cortex CN → Thalamus CN → Caudate-putamen and nucleus accumbens CN → Substantia nigra and ventral tegmental area CN → Cerebellum CN → Spinal cord Rostral nuclei (RN): Nucleus linearis, dorsal raphe, medial raphe, and raphe pontis Rostral projections RN → Amygdala RN → Cingulate cortex RN → Hippocampus RN → Hypothalamus RN → Neocortex RN → Septum RN → Thalamus RN → Ventral tegmental area	arousal (wakefulness) body temperature regulation emotion and mood, potentially including aggression feeding and energy homeostasis reward (minor role) sensory perception
Acetylcholine system	Cholinergic pathways: Forebrain cholinergic nuclei (FCN): Nucleus basalis of Meynert, medial septal nucleus, and diagonal band Forebrain nuclei projections FCN → Hippocampus FCN → Cerebral cortex FCN → Limbic cortex and sensory cortex Striatal tonically active cholinergic neurons (TAN) TAN → Medium spiny neuron Brainstem cholinergic nuclei (BCN): Pedunculopontine nucleus, laterodorsal tegmentum, medial habenula, and parabigeminal nucleus Brainstem nuclei projections BCN → Ventral tegmental area BCN → Thalamus	arousal (wakefulness) emotion and mood learning motor function motivation (motivational salience) short-term memory reward (minor role)
Adrenaline system	Adrenergic pathways: Rostral ventrolateral medulla (RVLM) projections RVLM → Spinal cord RVLM → Brain stem RVLM → Hypothalamus	medullary control of respiration sympathetic nervous system feeding and energy homeostasis arousal stress

Drug effects

Understanding the effects of drugs on neurotransmitters comprises a significant portion of research initiatives in the field of neuroscience. Most neuroscientists involved in this field of research believe that such efforts may further advance our understanding of the circuits responsible for various neurological diseases and disorders, as well as ways to effectively treat and someday possibly prevent or cure such illnesses.^{[medical citation needed]}

Drugs can influence behavior by altering neurotransmitter activity. For instance, drugs can decrease the rate of synthesis of neurotransmitters by affecting the synthetic enzyme(s) for that neurotransmitter. When neurotransmitter syntheses are blocked, the amount of neurotransmitters available for release becomes substantially lower, resulting in a decrease in neurotransmitter activity. Some drugs block or stimulate the release of specific neurotransmitters. Alternatively, drugs can prevent neurotransmitter storage in synaptic vesicles by causing the synaptic vesicle membranes to leak. Drugs that prevent a neurotransmitter from binding to its receptor are called receptor antagonists. For example, drugs used to treat patients with schizophrenia such as haloperidol, chlorpromazine, and clozapine are antagonists at receptors in the brain for dopamine. Other drugs act by binding to a receptor and mimicking the normal neurotransmitter. Such drugs are called receptor agonists. An example of a receptor agonist is morphine, an opiate that mimics effects of the endogenous neurotransmitter β-endorphin to relieve pain. Other drugs interfere with the deactivation of a neurotransmitter after it has been released, thereby prolonging the action of a neurotransmitter. This can be accomplished by blocking re-uptake or inhibiting degradative enzymes. Lastly, drugs can also prevent an action potential from occurring, blocking neuronal activity throughout the central and peripheral nervous system. Drugs such as tetrodotoxin that block neural activity are typically lethal.^{[citation needed]}

Drugs targeting the neurotransmitter of major systems affect the whole system, which can explain the complexity of action of some drugs. Cocaine, for example, blocks the re-uptake of dopamine back into the presynaptic neuron, leaving the neurotransmitter molecules in the synaptic gap for an extended period of time. Since the dopamine remains in the synapse longer, the neurotransmitter continues to bind to the receptors on the postsynaptic neuron, eliciting a pleasurable emotional response. Physical addiction to cocaine may result from prolonged exposure to excess dopamine in the synapses, which leads to the downregulation of some post-synaptic receptors. After the effects of the drug wear off, an individual can become depressed due to decreased probability of the neurotransmitter binding to a receptor. Fluoxetine is a selective serotonin re-uptake inhibitor (SSRI), which blocks re-uptake of serotonin by the presynaptic cell which increases the amount of serotonin present at the synapse and furthermore allows it to remain there longer, providing potential for the effect of naturally released serotonin.AMPT prevents the conversion of tyrosine to L-DOPA, the precursor to dopamine; reserpine prevents dopamine storage within vesicles; and deprenyl inhibits monoamine oxidase (MAO)-B and thus increases dopamine levels.^{[citation needed]}

Drug–neurotransmitter interactions

Drug	Interacts with	Receptor interaction	Type	Effects
Botulinum toxin (Botox)	Acetylcholine	–	Antagonist	Blocks acetylcholine release in PNS Prevents muscle contractions
Black widow spider venom	Acetylcholine	–	Agonist	Promotes acetylcholine release in PNS Stimulates muscle contractions
Neostigmine	Acetylcholine	–	–	Interferes with acetylcholinerase activity Increases effects of ACh at receptors Used to treat myasthenia gravis
Nicotine	Acetylcholine	Nicotinic (skeletal muscle)	Agonist	Increases ACh activity Increases attention Reinforcing effects
d-tubocurarine	Acetylcholine	Nicotinic (skeletal muscle)	Antagonist	Decreases activity at receptor site
Curare	Acetylcholine	Nicotinic (skeletal muscle)	Antagonist	Decreases ACh activity Prevents muscle contractions
Muscarine	Acetylcholine	Muscarinic (heart and smooth muscle)	Agonist	Increases ACh activity Toxic
Atropine	Acetylcholine	Muscarinic (heart and smooth muscle)	Antagonist	Blocks pupil constriction Blocks saliva production
Scopolamine (hyoscine)	Acetylcholine	Muscarinic (heart and smooth muscle)	Antagonist	Treats motion sickness and postoperative nausea and vomiting
AMPT	Dopamine/norepinephrine	–	–	Inactivates tyrosine hydroxylase and inhibits dopamine production
Reserpine	Dopamine	–	–	Prevents storage of dopamine and other monoamines in synaptic vesicles Causes sedation and depression
Apomorphine	Dopamine	D2 receptor (presynaptic autoreceptors/postsynaptic receptors)	Antagonist (low dose) / direct agonist (high dose)	Low dose: blocks autoreceptors High dose: stimulates postsynaptic receptors
Amphetamine	Dopamine/norepinephrine	–	Indirect agonist	Releases dopamine, noradrenaline, and serotonin Blocks reuptake
Methamphetamine	Dopamine/norepinephrine	–	–	Releases dopamine and noradrenaline Blocks reuptake
Methylphenidate	Dopamine	–	–	Blocks reuptake Enhances attention and impulse control in ADHD
Cocaine	Dopamine	–	Indirect agonist	Blocks reuptake into presynapse Blocks voltage-dependent sodium channels Can be used as a topical anesthetic (eye drops)
Deprenyl	Dopamine	–	Agonist	Inhibits MAO-B Prevents destruction of dopamine
Chlorpromazine	Dopamine	D2 Receptors	Antagonist	Blocks D2 receptors Alleviates hallucinations
MPTP	Dopamine	–	–	Results in Parkinson-like symptoms
PCPA	Serotonin (5-HT)	–	Antagonist	Disrupts serotonin synthesis by blocking the activity of tryptophan hydroxylase
Ondansetron	Serotonin (5-HT)	5-HT3 receptors	Antagonist	Reduces side effects of chemotherapy and radiation Reduces nausea and vomiting
Buspirone	Serotonin (5-HT)	5-HT1A receptors	Partial agonist	Treats symptoms of anxiety and depression
Fluoxetine	Serotonin (5-HT)	supports 5-HT reuptake	SSRI	Inhibits reuptake of serotonin Treats depression, some anxiety disorders, and OCD Common examples: Prozac and Sarafem
Fenfluramine	Serotonin (5-HT)	–	–	Causes release of serotonin Inhibits reuptake of serotonin Used as an appetite suppressant
Lysergic acid diethylamide	Serotonin (5-HT)	Post-synaptic 5-HT2A receptors	Direct agonist	Produces visual perception distortions Stimulates 5-HT2A receptors in forebrain
Methylenedioxy­methamphetamine (MDMA)	Serotonin (5-HT)/norepinphrine	–	–	Stimulates release of serotonin and norepinephrine and inhibits the reuptake Causes excitatory and hallucinogenic effects
Strychnine	Glycine	–	Antagonist	Causes severe muscle spasms
Diphenhydramine	Histamine			Crosses blood–brain barrier to cause drowsiness
Tetrahydrocannabinol (THC)	Endocannabinoids	Cannabinoid (CB) receptors	Agonist	Produces analgesia and sedation Increases appetite Cognitive effects
Rimonabant	Endocannabinoids	Cannabinoid (CB) receptors	Antagonist	Suppresses appetite Used in smoking cessation
MAFP	Endocannabinoids	–	–	Inhibits FAAH Used in research to increase cannabinoid system activity
AM1172	Endocannabinoids	–	–	Blocks cannabinoid reuptake Used in research to increase cannabinoid system activity
Anandamide (endogenous)	–	Cannabinoid (CB) receptors; 5-HT3 receptors	–	Reduce nausea and vomiting
Caffeine	Adenosine	Adenosine receptors	Antagonist	Blocks adenosine receptors Increases wakefulness
PCP	Glutamate	NMDA receptor	Indirect antagonist	Blocks PCP binding site Prevents calcium ions from entering neurons Impairs learning
AP5	Glutamate	NMDA receptor	Antagonist	Blocks glutamate binding site on NMDA receptor Impairs synaptic plasticity and certain forms of learning
Ketamine	Glutamate	NMDA receptor	Antagonist	Used as anesthesia Induces trance-like state, helps with pain relief and sedation
NMDA	Glutamate	NMDA receptor	Agonist	Used in research to study NMDA receptor Ionotropic receptor
AMPA	Glutamate	AMPA receptor	Agonist	Used in research to study AMPA receptor Ionotropic receptor
Allyglycine	GABA	–	–	Inhibits GABA synthesis Causes seizures
Muscimol	GABA	GABA receptor	Agonist	Causes sedation
Bicuculine	GABA	GABA receptor	Antagonist	Causes Seizures
Benzodiazepines	GABA	GABAA receptor	Indirect agonists	Anxiolytic, sedation, memory impairment, muscle relaxation
Barbiturates	GABA	GABAA receptor	Indirect agonists	Sedation, memory impairment, muscle relaxation
Alcohol	GABA	GABA receptor	Indirect agonist	Sedation, memory impairment, muscle relaxation
Picrotoxin	GABA	GABAA receptor	Indirect antagonist	High doses cause seizures
Tiagabine	GABA	–	Antagonist	GABA transporter antagonist Increase availability of GABA Reduces the likelihood of seizures
Moclobemide	Norepinephrine	–	Agonist	Blocks MAO-A to treat depression
Idazoxan	Norepinephrine	alpha-2 adrenergic autoreceptors	Agonist	Blocks alpha-2 autoreceptors Used to study norepinephrine system
Fusaric acid	Norepinephrine	–	–	Inhibits activity of dopamine beta-hydroxylase which blocks the production of norepinephrine Used to study norepinephrine system without affecting dopamine system
Opiates (opium, morphine, heroin, and oxycodone)	Opioids	Opioid receptor	Agonists	Analgesia, sedation, and reinforcing effects
Naloxone	Opioids	–	Antagonist	Reverses opiate intoxication or overdose symptoms (i.e. problems with breathing)

Agonists

An agonist is a chemical capable of binding to a receptor, such as a neurotransmitter receptor, and initiating the same reaction typically produced by the binding of the endogenous substance. An agonist of a neurotransmitter will thus initiate the same receptor response as the transmitter. In neurons, an agonist drug may activate neurotransmitter receptors either directly or indirectly. Direct-binding agonists can be further characterized as full agonists, partial agonists, inverse agonists.

Direct agonists act similar to a neurotransmitter by binding directly to its associated receptor site(s), which may be located on the presynaptic neuron or postsynaptic neuron, or both. Typically, neurotransmitter receptors are located on the postsynaptic neuron, while neurotransmitter autoreceptors are located on the presynaptic neuron, as is the case for monoamine neurotransmitters; in some cases, a neurotransmitter utilizes retrograde neurotransmission, a type of feedback signaling in neurons where the neurotransmitter is released postsynaptically and binds to target receptors located on the presynaptic neuron.Nicotine, a compound found in tobacco, is a direct agonist of most nicotinic acetylcholine receptors, mainly located in cholinergic neurons.Opiates, such as morphine, heroin, hydrocodone, oxycodone, codeine, and methadone, are μ-opioid receptor agonists; this action mediates their euphoriant and pain relieving properties.

Indirect agonists increase the binding of neurotransmitters at their target receptors by stimulating the release or preventing the reuptake of neurotransmitters. Some indirect agonists trigger neurotransmitter release and prevent neurotransmitter reuptake. Amphetamine, for example, is an indirect agonist of postsynaptic dopamine, norepinephrine, and serotonin receptors in each their respective neurons; it produces both neurotransmitter release into the presynaptic neuron and subsequently the synaptic cleft and prevents their reuptake from the synaptic cleft by activating TAAR1, a presynaptic G protein-coupled receptor, and binding to a site on VMAT2, a type of monoamine transporter located on synaptic vesicles within monoamine neurons.

Antagonists

An antagonist is a chemical that acts within the body to reduce the physiological activity of another chemical substance (such as an opiate); especially one that opposes the action on the nervous system of a drug or a substance occurring naturally in the body by combining with and blocking its nervous receptor.

There are two main types of antagonist: direct-acting Antagonist and indirect-acting Antagonists:

1. Direct-acting antagonist- which takes up space present on receptors which are otherwise taken up by neurotransmitters themselves. This results in neurotransmitters being blocked from binding to the receptors. An example of one of the most common is called Atropine.
2. Indirect-acting antagonist- drugs that inhibit the release/production of neurotransmitters (e.g., Reserpine).

Drug antagonists

An antagonist drug is one that attaches (or binds) to a site called a receptor without activating that receptor to produce a biological response. It is therefore said to have no intrinsic activity. An antagonist may also be called a receptor "blocker" because they block the effect of an agonist at the site. The pharmacological effects of an antagonist, therefore, result in preventing the corresponding receptor site's agonists (e.g., drugs, hormones, neurotransmitters) from binding to and activating it. Antagonists may be "competitive" or "irreversible".

A competitive antagonist competes with an agonist for binding to the receptor. As the concentration of antagonist increases, the binding of the agonist is progressively inhibited, resulting in a decrease in the physiological response. High concentration of an antagonist can completely inhibit the response. This inhibition can be reversed, however, by an increase of the concentration of the agonist, since the agonist and antagonist compete for binding to the receptor. Competitive antagonists, therefore, can be characterized as shifting the dose–response relationship for the agonist to the right. In the presence of a competitive antagonist, it takes an increased concentration of the agonist to produce the same response observed in the absence of the antagonist.

An irreversible antagonist binds so strongly to the receptor as to render the receptor unavailable for binding to the agonist. Irreversible antagonists may even form covalent chemical bonds with the receptor. In either case, if the concentration of the irreversible antagonist is high enough, the number of unbound receptors remaining for agonist binding may be so low that even high concentrations of the agonist do not produce the maximum biological response.

Precursors

Biosynthetic pathways for catecholamines and trace amines in the human brain L-Phenylalanine L-Tyrosine L-DOPA Epinephrine Phenethylamine p-Tyramine Dopamine Norepinephrine N-Methylphenethylamine N-Methyltyramine p-Octopamine Synephrine 3-Methoxytyramine AADC AADC AADC primary pathway PNMT PNMT PNMT PNMT AAAH AAAH brain CYP2D6 minor pathway COMT DBH DBH In humans, catecholamines and phenethylaminergic trace amines are derived from the amino acid L-phenylalanine.

While intake of neurotransmitter precursors does increase neurotransmitter synthesis, evidence is mixed as to whether neurotransmitter release and postsynaptic receptor firing is increased. Even with increased neurotransmitter release, it is unclear whether this will result in a long-term increase in neurotransmitter signal strength, since the nervous system can adapt to changes such as increased neurotransmitter synthesis and may therefore maintain constant firing.^{[unreliable medical source?]} Some neurotransmitters may have a role in depression and there is some evidence to suggest that intake of precursors of these neurotransmitters may be useful in the treatment of mild and moderate depression.^{[unreliable medical source?]}

Catecholamine and trace amine precursors

L-DOPA, a precursor of dopamine that crosses the blood–brain barrier, is used in the treatment of Parkinson's disease. For depressed patients where low activity of the neurotransmitter norepinephrine is implicated, there is only little evidence for benefit of neurotransmitter precursor administration. L-phenylalanine and L-tyrosine are both precursors for dopamine, norepinephrine, and epinephrine. These conversions require vitamin B6, vitamin C, and S-adenosylmethionine. A few studies suggest potential antidepressant effects of L-phenylalanine and L-tyrosine, but there is much room for further research in this area.^{[unreliable medical source?]}

Serotonin precursors

Administration of L-tryptophan, a precursor for serotonin, is seen to double the production of serotonin in the brain. It is significantly more effective than a placebo in the treatment of mild and moderate depression.^{[unreliable medical source?]} This conversion requires vitamin C.5-hydroxytryptophan (5-HTP), also a precursor for serotonin, is more effective than a placebo.^{[unreliable medical source?]}

Diseases and disorders

Diseases and disorders may also affect specific neurotransmitter systems. The following are disorders involved in either an increase, decrease, or imbalance of certain neurotransmitters.^{[citation needed]}

Dopamine

For example, problems in producing dopamine (mainly in the substantia nigra) can result in Parkinson's disease, a disorder that affects a person's ability to move as they want to, resulting in stiffness, tremors or shaking, and other symptoms. Some studies suggest that having too little or too much dopamine or problems using dopamine in the thinking and feeling regions of the brain may play a role in disorders like schizophrenia or attention deficit hyperactivity disorder (ADHD). Dopamine is also involved in addiction and drug use, as most recreational drugs cause an influx of dopamine in the brain (especially opioid and methamphetamines) that produces a pleasurable feeling, which is why users constantly crave drugs.^{[citation needed]}

Serotonin

Similarly, after some research suggested that drugs that block the recycling, or reuptake, of serotonin seemed to help some people diagnosed with depression, it was theorized that people with depression might have lower-than-normal serotonin levels. Though widely popularized, this theory was not borne out in subsequent research. Therefore, selective serotonin reuptake inhibitors (SSRIs) are used to increase the amounts of serotonin in synapses.

Glutamate

CAPON binds nitric oxide synthase, regulating NMDA receptor–mediated glutamate neurotransmission

Furthermore, problems with producing or using glutamate have been suggestively and tentatively linked to many mental disorders, including autism, obsessive–compulsive disorder (OCD), schizophrenia, and depression. Having too much glutamate has been linked to neurological diseases such as Parkinson's disease, multiple sclerosis, Alzheimer's disease, stroke, and ALS (amyotrophic lateral sclerosis).

Neurotransmitter imbalance

Generally, there are no scientifically established "norms" for appropriate levels or "balances" of different neurotransmitters. In most cases, it is practically impossible to measure neurotransmitter levels in the brain or body at any given moment. Neurotransmitters regulate each other's release, and weak consistent imbalances in this mutual regulation were linked to temperament in healthy people. However, significant imbalances or disruptions in neurotransmitter systems are associated with various diseases and mental disorders, including Parkinson's disease, depression, insomnia, Attention Deficit Hyperactivity Disorder (ADHD), anxiety, memory loss, dramatic weight changes, and addictions. Some of these conditions are also related to neurotransmitter switching, a phenomenon where neurons change the type of neurotransmitters they release. Chronic physical or emotional stress can be a contributor to neurotransmitter system changes. Genetics also plays a role in neurotransmitter activities.

Apart from recreational use, medications that directly and indirectly interact with one or more transmitter or its receptor are commonly prescribed for psychiatric and psychological issues. Notably, drugs interacting with serotonin and norepinephrine are prescribed to patients with problems such as depression and anxiety—though the notion that there is much solid medical evidence to support such interventions has been widely criticized. Studies shown that dopamine imbalance has an influence on multiple sclerosis and other neurological disorders.

See also

• Medicine portal

• BK channel § Cellular level
• Kiss-and-run fusion
• Natural neuroactive substance
• Neuroendocrine
• Neuroendocrinology
• Neuropsychopharmacology
• Neurotransmission
• Neurotransmitter analog
• Neurotransmitter release
• Neural pathway
• Neuromodulation
• False neurotransmitter

Notes

1. In the central nervous system, anandamide other endocannabinoids utilize retrograde neurotransmission, since their release is postsynaptic, while their target receptor, cannabinoid receptor 1 (CB1), is presynaptic. The cannabis plant contains Δ⁹-tetrahydrocannabinol, which is a direct agonist at CB1.

1. GABA is a non-proteinogenic amino acid

References

1. Smelser, Neil J.; Baltes, Paul B. (2001). International encyclopedia of the social & behavioral sciences (1st ed.). Amsterdam New York: Elsevier. ISBN 978-0-08-043076-8.
2. Edwards, Robert H (December 1998). "Neurotransmitter release: Variations on a theme". Current Biology. 8 (24): R883 – R885. Bibcode:1998CBio....8.R883E. doi:10.1016/s0960-9822(07)00551-9. ISSN 0960-9822. PMID 9843673.
3. Cuevas J (1 January 2019). "Neurotransmitters and Their Life Cycle". Reference Module in Biomedical Sciences. Elsevier. doi:10.1016/b978-0-12-801238-3.11318-2. ISBN 978-0-12-801238-3.
4. Purves D, Augustine GJ, Fitzpatrick D, Katz LC, LaMantia AS, McNamara JO, Williams SM (2001). "Peptide Neurotransmitters". Neuroscience (2nd ed.). Sinauer Associates.
5. Xue, L.; Farrugia, G.; Miller, S. M.; Ferris, C. D.; Snyder, S. H.; Szurszewski, J. H. (15 February 2000). "Carbon monoxide and nitric oxide as coneurotransmitters in the enteric nervous system: Evidence from genomic deletion of biosynthetic enzymes". Proceedings of the National Academy of Sciences. 97 (4): 1851–1855. Bibcode:2000PNAS...97.1851X. doi:10.1073/pnas.97.4.1851. ISSN 0027-8424. PMC 26525. PMID 10677545.
6. Sanders KM, Ward SM (January 2019). "Nitric oxide and its role as a non-adrenergic, non-cholinergic inhibitory neurotransmitter in the gastrointestinal tract". British Journal of Pharmacology. 176 (2): 212–227. doi:10.1111/bph.14459. PMC 6295421. PMID 30063800.
7. Elias LJ, Saucier DM (2005). Neuropsychology: Clinical and Experimental Foundations. Boston: Pearson.
8. Di Chiara G, Morelli M, Consolo S (June 1994). "Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions". Trends in Neurosciences. 17 (6): 228–233. doi:10.1016/0166-2236(94)90005-1. PMID 7521083. S2CID 32085555.
9. Chergui K, Suaud-Chagny MF, Gonon F (October 1994). "Nonlinear relationship between impulse flow, dopamine release and dopamine elimination in the rat brain in vivo". Neuroscience. 62 (3): 641–645. doi:10.1016/0306-4522(94)90465-0. PMID 7870295. S2CID 20465561.
10. Mustafa, Asif K.; Kim, Paul M.; Snyder, Solomon H. (August 2004). "D-Serine as a putative glial neurotransmitter". Neuron Glia Biology. 1 (3): 275–281. doi:10.1017/S1740925X05000141. ISSN 1741-0533. PMC 1403160. PMID 16543946.
11. Wolosker, Herman; Dumin, Elena; Balan, Livia; Foltyn, Veronika N. (July 2008). "d-Amino acids in the brain: d-serine in neurotransmission and neurodegeneration: d-Serine in neurotransmission and neurodegeneration". FEBS Journal. 275 (14): 3514–3526. doi:10.1111/j.1742-4658.2008.06515.x. PMID 18564180. S2CID 25735605.
12. Thapa S, Lv M, Xu H (30 November 2017). "Acetylcholinesterase: A Primary Target for Drugs and Insecticides". Mini Reviews in Medicinal Chemistry. 17 (17): 1665–1676. doi:10.2174/1389557517666170120153930. PMID 28117022.
13. Vasica G, Tennant CC (September 2002). "Cocaine use and cardiovascular complications". The Medical Journal of Australia. 177 (5): 260–262. doi:10.5694/j.1326-5377.2002.tb04761.x. PMID 12197823. S2CID 18572638.
14. Saladin, Kenneth S. Anatomy and Physiology: The Unity of Form and Function. McGraw Hill. 2009 ISBN 0-07-727620-5
15. Teleanu, Raluca Ioana; Niculescu, Adelina-Gabriela; Roza, Eugenia; Vladâcenco, Oana; Grumezescu, Alexandru Mihai; Teleanu, Daniel Mihai (25 May 2022). "Neurotransmitters—Key Factors in Neurological and Neurodegenerative Disorders of the Central Nervous System". International Journal of Molecular Sciences. 23 (11): 5954. doi:10.3390/ijms23115954. ISSN 1422-0067. PMC 9180936. PMID 35682631.
16. Breedlove SM, Watson NV (2013). Biological psychology : an introduction to behavioral, cognitive, and clinical neuroscience (Seventh ed.). Sunderland, MA: Sinauer Associates. ISBN 978-0878939275.
17. Whishaw B, Kolb IQ (2014). An introduction to brain and behavior (4th ed.). New York, NY: Worth Publishers. pp. 150–151. ISBN 978-1429242288.
18. Purves, Dale; Augustine, George J.; Fitzpatrick, David; Katz, Lawrence C.; LaMantia, Anthony-Samuel; McNamara, James O.; Williams, S. Mark (2001), "Excitatory and Inhibitory Postsynaptic Potentials", Neuroscience. 2nd edition, Sinauer Associates, retrieved 14 July 2023
19. Peters A, Palay SL (December 1996). "The morphology of synapses". Journal of Neurocytology. 25 (12): 687–700. doi:10.1007/BF02284835. PMID 9023718. S2CID 29365393.
20. Shier D, Butler J, Lewis R (5 January 2015). Hole's human anatomy & physiology (Fourteenth ed.). New York, NY. ISBN 978-0-07-802429-0. OCLC 881146319.{{cite book}}: CS1 maint: location missing publisher (link)
21. Whishaw B, Kolb IQ (2014). An introduction to brain and behavior (4th ed.). New York, NY: Worth Publishers. ISBN 978-1429242288.
22. Gross L (November 2006). ""Supporting" players take the lead in protecting the overstimulated brain". PLOS Biology. 4 (11): e371. doi:10.1371/journal.pbio.0040371. PMC 1609133. PMID 20076484.
23. Yang JL, Sykora P, Wilson DM, Mattson MP, Bohr VA (August 2011). "The excitatory neurotransmitter glutamate stimulates DNA repair to increase neuronal resiliency". Mechanisms of Ageing and Development. 132 (8–9): 405–11. doi:10.1016/j.mad.2011.06.005. PMC 3367503. PMID 21729715.
24. Orexin receptor antagonists a new class of sleeping pill, National Sleep Foundation.
25. Rajendra, Sundran; Lynch, Joseph W.; Schofield, Peter R. (January 1997). "The glycine receptor". Pharmacology & Therapeutics. 73 (2): 121–146. doi:10.1016/S0163-7258(96)00163-5. PMID 9131721.
26. "Acetylcholine Receptors". Ebi.ac.uk. Retrieved 25 August 2014.
27. Fahn, Stanley; Jankovic, Joseph; Hallett, Mark (1 January 2011), Fahn, Stanley; Jankovic, Joseph; Hallett, Mark (eds.), "Chapter 3 - Functional neuroanatomy of the basal ganglia", Principles and Practice of Movement Disorders (Second Edition), Edinburgh: W.B. Saunders, pp. 55–65, doi:10.1016/b978-1-4377-2369-4.00003-2, ISBN 978-1-4377-2369-4, retrieved 25 November 2024
28. Schacter, Gilbert and Weger. Psychology.United States of America.2009.Print.
29. Terry, Natalie; Margolis, Kara Gross (2017), Greenwood-Van Meerveld, Beverley (ed.), "Serotonergic Mechanisms Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance", Gastrointestinal Pharmacology, vol. 239, Cham: Springer International Publishing, pp. 319–342, doi:10.1007/164_2016_103, ISBN 978-3-319-56360-2, PMC 5526216, PMID 28035530
30. University of Bristol. "Introduction to Serotonin". Retrieved 15 October 2009.
31. Sheffler, Zachary M.; Reddy, Vamsi; Pillarisetty, Leela Sharath (2023), "Physiology, Neurotransmitters", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 30969716, retrieved 16 July 2023
32. Fitzgerald, P. J. (April 2015). "Noradrenaline transmission reducing drugs may protect against a broad range of diseases". Autonomic and Autacoid Pharmacology. 34 (3–4): 15–26. doi:10.1111/aap.12019. ISSN 1474-8665. PMID 25271382.
33. Bouras, Nadia N.; Mack, Nancy R.; Gao, Wen-Jun (17 April 2023). "Prefrontal modulation of anxiety through a lens of noradrenergic signaling". Frontiers in Systems Neuroscience. 17. doi:10.3389/fnsys.2023.1173326. ISSN 1662-5137. PMC 10149815. PMID 37139472.
34. Moret, Chantal; Briley, Mike (31 May 2011). "The importance of norepinephrine in depression". Neuropsychiatric Disease and Treatment. 7 (Supplement 1): 9–13. doi:10.2147/NDT.S19619. PMC 3131098. PMID 21750623.
35. Prasad BV (2020). Examining Biological Foundations of Human Behavior. United States of America: IGI Global. p. 81. ISBN 978-1799-8286-17.
36. Sapolsky R (2005). "Biology and Human Behavior: The Neurological Origins of Individuality, 2nd". The Teaching Company. see pages 13 & 14 of Guide Book
37. Snyder SH, Innis RB (1979). "Peptide neurotransmitters". Annual Review of Biochemistry. 48: 755–82. doi:10.1146/annurev.bi.48.070179.003543. PMID 38738.
38. Corbière A, Vaudry H, Chan P, Walet-Balieu ML, Lecroq T, Lefebvre A, et al. (18 September 2019). "Strategies for the Identification of Bioactive Neuropeptides in Vertebrates". Frontiers in Neuroscience. 13: 948. doi:10.3389/fnins.2019.00948. PMC 6759750. PMID 31619945.
39. Fricker LD, Devi LA (May 2018). "Orphan neuropeptides and receptors: Novel therapeutic targets". Pharmacology & Therapeutics. 185: 26–33. doi:10.1016/j.pharmthera.2017.11.006. PMC 5899030. PMID 29174650.
40. Kodirov SA, Takizawa S, Joseph J, Kandel ER, Shumyatsky GP, Bolshakov VY (October 2006). "Synaptically released zinc gates long-term potentiation in fear conditioning pathways". Proceedings of the National Academy of Sciences of the United States of America. 103 (41): 15218–23. Bibcode:2006PNAS..10315218K. doi:10.1073/pnas.0607131103. PMC 1622803. PMID 17005717.
41. "International Symposium on Nitric Oxide – Dr. John Andrews – MaRS". MaRS. Archived from the original on 14 October 2014.
42. "Dopamine: Biological activity". IUPHAR/BPS guide to pharmacology. International Union of Basic and Clinical Pharmacology. Retrieved 29 January 2016.
43. Grandy DK, Miller GM, Li JX (February 2016). ""TAARgeting Addiction"--The Alamo Bears Witness to Another Revolution: An Overview of the Plenary Symposium of the 2015 Behavior, Biology and Chemistry Conference". Drug and Alcohol Dependence. 159: 9–16. doi:10.1016/j.drugalcdep.2015.11.014. PMC 4724540. PMID 26644139. TAAR1 is a high-affinity receptor for METH/AMPH and DA
44. Lin Y, Hall RA, Kuhar MJ (October 2011). "CART peptide stimulation of G protein-mediated signaling in differentiated PC12 cells: identification of PACAP 6-38 as a CART receptor antagonist". Neuropeptides. 45 (5): 351–8. doi:10.1016/j.npep.2011.07.006. PMC 3170513. PMID 21855138.
45. Miller GM (January 2011). "The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity". Journal of Neurochemistry. 116 (2): 164–76. doi:10.1111/j.1471-4159.2010.07109.x. PMC 3005101. PMID 21073468.
46. Eiden LE, Weihe E (January 2011). "VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse". Annals of the New York Academy of Sciences. 1216 (1): 86–98. Bibcode:2011NYASA1216...86E. doi:10.1111/j.1749-6632.2010.05906.x. PMC 4183197. PMID 21272013. VMAT2 is the CNS vesicular transporter for not only the biogenic amines DA, NE, EPI, 5-HT, and HIS, but likely also for the trace amines TYR, PEA, and thyronamine (THYR) ... [Trace aminergic] neurons in mammalian CNS would be identifiable as neurons expressing VMAT2 for storage, and the biosynthetic enzyme aromatic amino acid decarboxylase (AADC).
47. Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 6: Widely Projecting Systems: Monoamines, Acetylcholine, and Orexin". In Sydor A, Brown RY (eds.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. p. 155. ISBN 9780071481274. Different subregions of the VTA receive glutamatergic inputs from the prefrontal cortex, orexinergic inputs from the lateral hypothalamus, cholinergic and also glutamatergic and GABAergic inputs from the laterodorsal tegmental nucleus and pedunculopontine nucleus, noradrenergic inputs from the locus ceruleus, serotonergic inputs from the raphe nuclei, and GABAergic inputs from the nucleus accumbens and ventral pallidum.
48. Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 6: Widely Projecting Systems: Monoamines, Acetylcholine, and Orexin". In Sydor A, Brown RY (eds.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. pp. 145, 156–157. ISBN 9780071481274. Descending NE fibers modulate afferent pain signals. ... The locus ceruleus (LC), which is located on the floor of the fourth ventricle in the rostral pons, contains more than 50% of all noradrenergic neurons in the brain; it innervates both the forebrain (eg, it provides virtually all the NE to the cerebral cortex) and regions of the brainstem and spinal cord. ... The other noradrenergic neurons in the brain occur in loose collections of cells in the brainstem, including the lateral tegmental regions. These neurons project largely within the brainstem and spinal cord. NE, along with 5HT, ACh, histamine, and orexin, is a critical regulator of the sleep-wake cycle and of levels of arousal. ... LC firing may also increase anxiety ...Stimulation of β-adrenergic receptors in the amygdala results in enhanced memory for stimuli encoded under strong negative emotion ... Epinephrine occurs in only a small number of central neurons, all located in the medulla. Epinephrine is involved in visceral functions, such as control of respiration.
49. Rang HP (2003). Pharmacology. Edinburgh: Churchill Livingstone. pp. 474 for noradrenaline system, page 476 for dopamine system, page 480 for serotonin system and page 483 for cholinergic system. ISBN 978-0-443-07145-4.
50. Iwańczuk W, Guźniczak P (2015). "Neurophysiological foundations of sleep, arousal, awareness and consciousness phenomena. Part 1". Anaesthesiology Intensive Therapy. 47 (2): 162–7. doi:10.5603/AIT.2015.0015. PMID 25940332. The ascending reticular activating system (ARAS) is responsible for a sustained wakefulness state. ... The thalamic projection is dominated by cholinergic neurons originating from the pedunculopontine tegmental nucleus of pons and midbrain (PPT) and laterodorsal tegmental nucleus of pons and midbrain (LDT) nuclei [17, 18]. The hypothalamic projection involves noradrenergic neurons of the locus coeruleus (LC) and serotoninergic neurons of the dorsal and median raphe nuclei (DR), which pass through the lateral hypothalamus and reach axons of the histaminergic tubero-mamillary nucleus (TMN), together forming a pathway extending into the forebrain, cortex and hippocampus. Cortical arousal also takes advantage of dopaminergic neurons of the substantia nigra (SN), ventral tegmenti area (VTA) and the periaqueductal grey area (PAG). Fewer cholinergic neurons of the pons and midbrain send projections to the forebrain along the ventral pathway, bypassing the thalamus [19, 20].
51. Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 12: Sleep and Arousal". In Sydor A, Brown RY (eds.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York, USA: McGraw-Hill Medical. p. 295. ISBN 9780071481274. The ARAS is a complex structure consisting of several different circuits including the four monoaminergic pathways ... The norepinephrine pathway originates from the locus ceruleus (LC) and related brainstem nuclei; the serotonergic neurons originate from the raphe nuclei within the brainstem as well; the dopaminergic neurons originate in ventral tegmental area (VTA); and the histaminergic pathway originates from neurons in the tuberomammillary nucleus (TMN) of the posterior hypothalamus. As discussed in Chapter 6, these neurons project widely throughout the brain from restricted collections of cell bodies. Norepinephrine, serotonin, dopamine, and histamine have complex modulatory functions and, in general, promote wakefulness. The PT in the brain stem is also an important component of the ARAS. Activity of PT cholinergic neurons (REM-on cells) promotes REM sleep. During waking, REM-on cells are inhibited by a subset of ARAS norepinephrine and serotonin neurons called REM-off cells.
52. Rinaman L (February 2011). "Hindbrain noradrenergic A2 neurons: diverse roles in autonomic, endocrine, cognitive, and behavioral functions". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 300 (2): R222-35. doi:10.1152/ajpregu.00556.2010. PMC 3043801. PMID 20962208.
53. Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 6: Widely Projecting Systems: Monoamines, Acetylcholine, and Orexin". In Sydor A, Brown RY (eds.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. pp. 147–148, 154–157. ISBN 9780071481274. Neurons from the SNc densely innervate the dorsal striatum where they play a critical role in the learning and execution of motor programs. Neurons from the VTA innervate the ventral striatum (nucleus accumbens), olfactory bulb, amygdala, hippocampus, orbital and medial prefrontal cortex, and cingulate cortex. VTA DA neurons play a critical role in motivation, reward-related behavior, attention, and multiple forms of memory. ... Thus, acting in diverse terminal fields, dopamine confers motivational salience ("wanting") on the reward itself or associated cues (nucleus accumbens shell region), updates the value placed on different goals in light of this new experience (orbital prefrontal cortex), helps consolidate multiple forms of memory (amygdala and hippocampus), and encodes new motor programs that will facilitate obtaining this reward in the future (nucleus accumbens core region and dorsal striatum). ... DA has multiple actions in the prefrontal cortex. It promotes the "cognitive control" of behavior: the selection and successful monitoring of behavior to facilitate attainment of chosen goals. Aspects of cognitive control in which DA plays a role include working memory, the ability to hold information "on line" in order to guide actions, suppression of prepotent behaviors that compete with goal-directed actions, and control of attention and thus the ability to overcome distractions. ... Noradrenergic projections from the LC thus interact with dopaminergic projections from the VTA to regulate cognitive control. ...
54. Calipari ES, Bagot RC, Purushothaman I, Davidson TJ, Yorgason JT, Peña CJ, et al. (March 2016). "In vivo imaging identifies temporal signature of D1 and D2 medium spiny neurons in cocaine reward". Proceedings of the National Academy of Sciences of the United States of America. 113 (10): 2726–31. Bibcode:2016PNAS..113.2726C. doi:10.1073/pnas.1521238113. PMC 4791010. PMID 26831103. Previous work has demonstrated that optogenetically stimulating D1 MSNs promotes reward, whereas stimulating D2 MSNs produces aversion.
55. Ikemoto S (November 2010). "Brain reward circuitry beyond the mesolimbic dopamine system: a neurobiological theory". Neuroscience and Biobehavioral Reviews. 35 (2): 129–50. doi:10.1016/j.neubiorev.2010.02.001. PMC 2894302. PMID 20149820. Recent studies on intracranial self-administration of neurochemicals (drugs) found that rats learn to self-administer various drugs into the mesolimbic dopamine structures–the posterior ventral tegmental area, medial shell nucleus accumbens and medial olfactory tubercle. ... In the 1970s it was recognized that the olfactory tubercle contains a striatal component, which is filled with GABAergic medium spiny neurons receiving glutamatergic inputs form cortical regions and dopaminergic inputs from the VTA and projecting to the ventral pallidum just like the nucleus accumbens
    Figure 3: The ventral striatum and self-administration of amphetamine
56. Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 6: Widely Projecting Systems: Monoamines, Acetylcholine, and Orexin". In Sydor A, Brown RY (eds.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. pp. 175–176. ISBN 9780071481274. Within the brain, histamine is synthesized exclusively by neurons with their cell bodies in the tuberomammillary nucleus (TMN) that lies within the posterior hypothalamus. There are approximately 64000 histaminergic neurons per side in humans. These cells project throughout the brain and spinal cord. Areas that receive especially dense projections include the cerebral cortex, hippocampus, neostriatum, nucleus accumbens, amygdala, and hypothalamus.  ... While the best characterized function of the histamine system in the brain is regulation of sleep and arousal, histamine is also involved in learning and memory ...It also appears that histamine is involved in the regulation of feeding and energy balance.
57. Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 6: Widely Projecting Systems: Monoamines, Acetylcholine, and Orexin". In Sydor A, Brown RY (eds.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. pp. 158–160. ISBN 9780071481274. [The] dorsal raphe preferentially innervates the cerebral cortex, thalamus, striatal regions (caudate-putamen and nucleus accumbens), and dopaminergic nuclei of the midbrain (eg, the substantia nigra and ventral tegmental area), while the median raphe innervates the hippocampus, septum, and other structures of the limbic forebrain. ... it is clear that 5HT influences sleep, arousal, attention, processing of sensory information in the cerebral cortex, and important aspects of emotion (likely including aggression) and mood regulation. ...The rostral nuclei, which include the nucleus linearis, dorsal raphe, medial raphe, and raphe pontis, innervate most of the brain, including the cerebellum. The caudal nuclei, which comprise the raphe magnus, raphe pallidus, and raphe obscuris, have more limited projections that terminate in the cerebellum, brainstem, and spinal cord.
58. Nestler EJ. "Brain Reward Pathways". Icahn School of Medicine at Mount Sinai. Nestler Lab. Retrieved 16 August 2014. The dorsal raphe is the primary site of serotonergic neurons in the brain, which, like noradrenergic neurons, pervasively modulate brain function to regulate the state of activation and mood of the organism.
59. Marston OJ, Garfield AS, Heisler LK (June 2011). "Role of central serotonin and melanocortin systems in the control of energy balance". European Journal of Pharmacology. 660 (1): 70–9. doi:10.1016/j.ejphar.2010.12.024. PMID 21216242.
60. Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 6: Widely Projecting Systems: Monoamines, Acetylcholine, and Orexin". In Sydor A, Brown RY (eds.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. pp. 167–175. ISBN 9780071481274. The basal forebrain cholinergic nuclei are comprised the medial septal nucleus (Ch1), the vertical nucleus of the diagonal band (Ch2), the horizontal limb of the diagonal band (Ch3), and the nucleus basalis of Meynert (Ch4). Brainstem cholinergic nuclei include the pedunculopontine nucleus (Ch5), the laterodorsal tegmental nucleus (Ch6), the medial habenula (Ch7), and the parabigeminal nucleus (Ch8).
61. Guyenet PG, Stornetta RL, Bochorishvili G, Depuy SD, Burke PG, Abbott SB (August 2013). "C1 neurons: the body's EMTs". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 305 (3): R187-204. doi:10.1152/ajpregu.00054.2013. PMC 3743001. PMID 23697799.
62. Stornetta RL, Guyenet PG (March 2018). "C1 neurons: a nodal point for stress?". Experimental Physiology. 103 (3): 332–336. doi:10.1113/EP086435. PMC 5832554. PMID 29080216.
63. "Neuron Conversations: How Brain Cells Communicate". Brainfacts.org. Retrieved 2 December 2014.
64. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schütz G, et al. (November 2008). "Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum". Cell. 135 (5): 825–37. doi:10.1016/j.cell.2008.09.059. PMC 2614332. PMID 19041748.
65. Carlson, N. R., & Birkett, M. A. (2017). Physiology of Behavior (12th ed.). Pearson, pp. 100–115. ISBN 978-0134080918
66. "CDC Strychnine. Facts about Strychnine". Public Health Emergency Preparedness & Response. Retrieved 7 May 2018.
67. "Neurotransmitters and Drugs Chart". Ocw.mit.edu. Retrieved 25 August 2014.
68. "Agonist – Definition and More from the Free Merriam-Webster Dictionary". Merriam-webster.com. Retrieved 25 August 2014.
69. Atack J., Lavreysen H. (2010) Agonist. In: Stolerman I.P. (eds) Encyclopedia of Psychopharmacology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68706-1_1565
70. Roth BL (February 2016). "DREADDs for Neuroscientists". Neuron. 89 (4): 683–694. doi:10.1016/j.neuron.2016.01.040. PMC 4759656. PMID 26889809.
71. Ries RK, Fiellin DA, Miller SC (2009). Principles of addiction medicine (4th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. pp. 709–710. ISBN 9780781774772. Retrieved 16 August 2015.
72. Flores A, Maldonado R, Berrendero F (December 2013). "Cannabinoid-hypocretin cross-talk in the central nervous system: what we know so far". Frontiers in Neuroscience. 7: 256. doi:10.3389/fnins.2013.00256. PMC 3868890. PMID 24391536.
     • Figure 1: Schematic of brain CB1 expression and orexinergic neurons expressing OX1 or OX2
     • Figure 2: Synaptic signaling mechanisms in cannabinoid and orexin systems
73. "Antagonist". Medical definition of Antagonist. Retrieved 5 November 2014.
74. Goeders NE (2001). "Antagonist". Encyclopedia of Drugs, Alcohol, and Addictive Behavior. Retrieved 2 December 2014.
75. Broadley KJ (March 2010). "The vascular effects of trace amines and amphetamines". Pharmacology & Therapeutics. 125 (3): 363–375. doi:10.1016/j.pharmthera.2009.11.005. PMID 19948186.
76. Lindemann L, Hoener MC (May 2005). "A renaissance in trace amines inspired by a novel GPCR family". Trends in Pharmacological Sciences. 26 (5): 274–281. doi:10.1016/j.tips.2005.03.007. PMID 15860375.
77. Wang X, Li J, Dong G, Yue J (February 2014). "The endogenous substrates of brain CYP2D". European Journal of Pharmacology. 724: 211–218. doi:10.1016/j.ejphar.2013.12.025. PMID 24374199.
78. Meyers S (February 2000). "Use of neurotransmitter precursors for treatment of depression" (PDF). Alternative Medicine Review. 5 (1): 64–71. PMID 10696120. Archived from the original (PDF) on 5 August 2004.
79. van Praag HM (March 1981). "Management of depression with serotonin precursors". Biological Psychiatry. 16 (3): 291–310. PMID 6164407.
80. Healy D (April 2015). "Serotonin and depression". BMJ. 350: h1771. doi:10.1136/bmj.h1771. PMID 25900074. S2CID 38726584.
81. "NIMH Brain Basics". U.S. National Institutes of Health. Archived from the original on 29 October 2014. Retrieved 29 October 2014.
82. Bittigau P, Ikonomidou C (November 1997). "Glutamate in neurologic diseases". Journal of Child Neurology. 12 (8): 471–85. doi:10.1177/088307389701200802. PMID 9430311. S2CID 1258390.
83. Netter, P. (1991) Biochemical variables in the study of temperament. In Strelau, J. & Angleitner, A. (Eds.), Explorations in temperament: International perspectives on theory and measurement 147–161. New York: Plenum Press.
84. Trofimova I, Robbins TW (May 2016). "Temperament and arousal systems: A new synthesis of differential psychology and functional neurochemistry". Neuroscience and Biobehavioral Reviews. 64: 382–402. doi:10.1016/j.neubiorev.2016.03.008. hdl:11375/26202. PMID 26969100. S2CID 13937324.
85. Cloninger CR, Svrakic DM, Przybeck TR. A psychobiological model of temperament and character" Arch Gen Psychiatry 1993; 50:975-990.
86. Trofimova IN (2016). "The interlocking between functional aspects of activities and a neurochemical model of adult temperament.". In Arnold MC (ed.). Temperaments: Individual Differences, Social and Environmental Influences and Impact on Quality of Life. New York: Nova Science Publishers, Inc. pp. 77–147.
87. Depue RA, Morrone-Strupinsky JV (June 2005). "A neurobehavioral model of affiliative bonding: implications for conceptualizing a human trait of affiliation". The Behavioral and Brain Sciences. 28 (3): 313–50, discussion 350–95. doi:10.1017/s0140525x05000063. PMID 16209725.
88. Spitzer, Nicholas C. (25 July 2017). "Neurotransmitter Switching in the Developing and Adult Brain". Annual Review of Neuroscience. 40 (1): 1–19. doi:10.1146/annurev-neuro-072116-031204. ISSN 0147-006X. PMID 28301776.
89. Dolan, Eric W. (13 November 2024). "Neurotransmitter switching in early development predicts autism-related behaviors". PsyPost - Psychology News. Retrieved 22 November 2024.
90. Pratelli, Marta; Hakimi, Anna M.; Thaker, Arth; Jang, Hyeonseok; Li, Hui-quan; Godavarthi, Swetha K.; Lim, Byung Kook; Spitzer, Nicholas C. (26 September 2024). "Drug-induced change in transmitter identity is a shared mechanism generating cognitive deficits". Nature Communications. 15 (1): 8260. Bibcode:2024NatCo..15.8260P. doi:10.1038/s41467-024-52451-x. ISSN 2041-1723. PMC 11427679. PMID 39327428.
91. Leo, J., & Lacasse, J. (10 October 2007). The Media and the Chemical Imbalance Theory of Depression. Retrieved 1 December 2014, from http://psychrights.org/articles/TheMediaandChemicalImbalanceTheoryofDepression.pdf
92. Dobryakova E, Genova HM, DeLuca J, Wylie GR (12 March 2015). "The dopamine imbalance hypothesis of fatigue in multiple sclerosis and other neurological disorders". Frontiers in Neurology. 6: 52. doi:10.3389/fneur.2015.00052. PMC 4357260. PMID 25814977.

External links

Wikimedia Commons has media related to Neurotransmitters.

Wikibooks has a book on the topic of: Neuroscience/Cellular Neurobiology/Neurotransmitters

• Purves, Dale; Augustine, George J.; Fitzpatrick, David; Katz, Lawrence C.; LaMantia, Anthony-Samuel; McNamara, James O.; Williams, S. Mark (2001). "Chapter 6. Neurotransmitters". What Defines a Neurotransmitter? (2nd ed.). Sunderland (MA): Sinauer Associates. ISBN 0-87893-742-0. {{cite book}}: |journal= ignored (help)
• Holz, Ronald W.; Fisher, Stephen K. (1999). "Chapter 10. Synaptic Transmission and Cellular Signaling: An Overview". In Siegel, George J; Agranoff, Bernard W; Albers, R Wayne; Fisher, Stephen K; Uhler, Michael D (eds.). Synaptic Transmission (6th ed.). Philadelphia: Lippincott-Raven. ISBN 0-397-51820-X. {{cite book}}: |journal= ignored (help)
• Neurotransmitters and Neuroactive Peptides at Neuroscience for Kids website